GW Pharmaceuticals announces plan for $225 million offering of ADSs

London, UK based GW Pharmaceuticals PLC (Nasdaq: GWPH) announced today it plans to sell $225 million of American Depositary Shares (ADSs) representing ordinary shares on the NASDAQ. No exact details are yet in place, so the offering is not yet guaranteed. Goldman Sachs & Co. LLC, Morgan Stanley, BofA Merrill Lynch and Cowen will be underwriters.

GW commercialized the world’s first plant-derived CBD prescription drug, Sativex® (nabiximols), which is approved for treatment of multiple sclerosis spasticity in many countries outside the USA. The company has a pipeline of other CBD product candidates in Phase 1 and 2 trials for glioblastoma, schizophrenia, and epilepsy.

Investor expectations are high for GW’s drug Epidiolex that treats childhood epilepsy. GW expects a decision from the FDA on it by mid-2018. “During 2017, a substantial body of positive clinical data on Epidiolex was published and presented… Beyond Epidiolex…we continue to advance a number of additional exciting pipeline clinical programs,” stated Justin Gover, GW’s Chief Executive Officer.”

GW’s revenue for the fiscal year 2017 ending September 30 was US$11.0 million, while the company lost US$175.9 million over the year. GW currently has $322.2 million in cash.

The stock closed today at $116, down 2.86%.

Source GW Pharma press release

GW Pharmaceuticals announces plan for $225 million offering of ADSs

About Cannin.com: Your Marijuana Stocks Resource

Cannin is your #1 resource for marijuana stocks. Our global team of experts evaluates all emerging marijuana stock investing opportunities. We aggregate hundreds of hours of research and provide tips on the best marijuana stock investments for 2020.

Use Cannin as your resource for:

Is it too late to invest in marijuana stocks? No! This is the perfect time to invest.

Many market analysts expect the legal marijuana industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in marijuana stocks is now.

Are you interested in marijuana stocks like Curaleaf, Trulieve, Aurora Cannabis, or Charlotte’s Web,?

Are you looking to buy stock in marijuana companies for 2020? Interested in emerging penny marijuana stocks? Looking for the best Canadian marijuana stocks to invest in? We can help.

Predict price movements of marijuana stocks several hours in advance with our proprietary algorithmic stock trading software.

+25% Gains in 2020
+49.8% Gains in 2019
108% Backtested since 2012

We’re so confident you’ll love our algotrading marijuana stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.

Profit from the best marijuana stocks – we’ll show you how at cannin.com.

Marijuana Stocks, Pot Stocks, Algorithmic Stock Trading, Best Hemp Stocks to Invest In

GW Pharmaceuticals announces plan for $225 million offering of ADSs